ATAI AtaiBeckley Inc.
ATAI AtaiBeckley Inc.
Healthcare · Biotechnology
No longer tracked since 2026-09-11 — left the market.
Market read
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Reported EPS $-0.09 versus analyst consensus of $-0.11 (+19.4%).
full note →Against street estimates
How ATAI's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
News (last pull)
Headlines about ATAI from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 42 days ago · Sep 11
- AtaiBeckley sale to Lilly pays $6.75 plus CVR | ATAI 8-K Filing
- AtaiBeckley Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | MarketScreener
- ATAI Beckley earnings on deck as investors eye Lilly deal By Investing.com
- AtaiBeckley (NASDAQ: ATAI) to be acquired by Eli Lilly in $6.75 cash deal plus CVR
- ATAI Stock Soars As Eli Lilly Takeover Talks Heat Up
ATAI research tape
44 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.